TRPV1 belongs to the transient receptor potential (TRP) superfamily of ion channels. It was first characterised as the molecular target of capsaicin , the compound responsible for the heat sensation produced by chilli peppers , and is sometimes called the capsaicin receptor as a result. The channel is a homotetrameric protein; each subunit carries six transmembrane domains and an intracellular ankyrin-repeat domain involved in regulatory protein interactions.
The receptor sits at the intersection of the endocannabinoid system and classical pain signalling pathways. Anandamide (N-arachidonoylethanolamine), an endogenous cannabinoid, can activate TRPV1 in addition to acting on CB1 receptors, which has led researchers to classify TRPV1 as an endocannabinoid-responsive channel rather than a canonical cannabinoid receptor. Other endogenous TRPV1 agonists under study include N-arachidonoyl dopamine (NADA) and certain oxidised derivatives of arachidonic acid.
On activation, TRPV1 permits an inward flux of calcium and sodium ions, depolarising the cell. Prolonged or repeated activation produces a state of desensitisation, during which the channel becomes temporarily unresponsive to further stimuli. The mechanisms underpinning desensitisation involve calcineurin-mediated dephosphorylation and intracellular calcium dynamics. It is worth noting that TRPV1 expression has been reported in non-neuronal tissues , including keratinocytes, mast cells, and epithelial cells of the bladder and gut; though the functional significance of these peripheral populations continues to be characterised in preclinical literature.
Some researchers have proposed, as a working hypothesis, that dysregulated TRPV1 tone may contribute to altered endocannabinoid signalling in various physiological states. This remains speculative: the hypothesis is based largely on animal models and in vitro data, and no causal relationship has been established in humans. TRPV1 remains an active area of pharmacological research, but no approved therapeutic agent in Australia is indicated on the basis of TRPV1 modulation as a primary mechanism.
Sources: